GLP-1 Receptor Agonists
34 articles on GLP-1 Receptor Agonists, written by Shotlee and medically reviewed for clinical accuracy.
GLP-1 Drugs for Alcohol Use Disorder: The Future of Addiction Treatment?
GLP-1 receptor agonists, widely known for their efficacy in weight management and type 2 diabetes, are showing remarkable promise in addressing Alcohol Use Disorder (AUD). Emerging research suggests these injectable therapies may fundamentally alter the brain's reward pathways, offering a novel pharmaceutical path for those struggling with heavy drinking.
6 min read
GLP-1 Drugs Show New Promise in Cardiovascular Procedures
New research suggests that GLP-1 receptor agonists, known for their roles in diabetes and weight management, may offer significant cardiovascular protection for patients undergoing complex procedures like TAVR and carotid artery stenting.
7 min read
Aston University Investigates Weight-Loss Drugs for PCOS Treatment
A gynaecologist at Aston University has won a £60,000 NHS research grant to probe the potential of weight-loss drugs like Ozempic and Mounjaro in treating polycystic ovary syndrome (PCOS). This initiative aims to evaluate their impact on metabolic health and fertility in affected women. Discover the project's details and why it matters for patient care.
6 min read
Social Media Reveals GLP-1 Side Effects Missed in Clinical Trials
Social media is spotlighting GLP-1 receptor agonist side effects that clinical trials overlooked, according to a new study in Nature Health. Researchers sifted through 410,198 Reddit posts on semaglutide and tirzepatide, finding 43.5% of users reporting issues like nausea and fatigue. These insights reveal patient concerns beyond traditional data.
4 min read
GLP-1 and SGLT2 Combo Cuts Mortality 29% in T2D Study
A large German study reveals that pairing GLP-1 receptor agonists with SGLT2 inhibitors significantly lowers all-cause mortality and cardiovascular risks in type 2 diabetes patients compared to SGLT2 inhibitors alone. Common combinations like dulaglutide plus empagliflozin showed a 29% mortality reduction. Experts highlight synergy but urge caution on potential harms.
5 min read
Genetic Variants May Reduce GLP-1 Diabetes Drug Effectiveness
A new Stanford Medicine study uncovers why GLP-1 receptor agonists may not work as well for some Type 2 diabetes patients: certain genetic variants lead to GLP-1 resistance. Carried by about 10% of the population, these variants result in higher but less effective GLP-1 levels. This could guide faster, personalized treatment switches.
6 min read
Study: Semaglutide Does Not Raise NAION Risk in Obesity, Diabetes
A large study presented in San Diego reveals semaglutide use is not associated with higher risk of non-arteritic anterior ischemic optic neuropathy (NAION) in patients with overweight or obesity. In fact, it lowered NAION risk by 64% among those with type 2 diabetes compared to non-GLP-1 therapies. Experts emphasize continued monitoring of blood sugar and blood pressure.
5 min read
GLP-1 Weight Loss Consistent Across Race, Age, BMI—But Not Sex
GLP-1 receptor agonists like semaglutide show consistent weight loss efficacy across diverse groups, but a notable sex difference emerges: women average 10.9% body weight loss versus 6.8% for men. This JAMA meta-analysis reassures clinicians while highlighting areas for further research. Experts explain why this matters for personalized obesity care.
5 min read
New Diabetes Drug UBT251 Beats Ozempic in Phase 2 Trial
In a Phase 2 clinical trial in China, Novo Nordisk's experimental drug UBT251 surpassed Ozempic, achieving greater reductions in blood sugar (up to 2.16% HbA1c drop) and body weight (up to 9.8% loss). This marks a potential advancement for type 2 diabetes management. Patients on semaglutide saw 1.77% HbA1c and 4.8% weight reductions, while placebo groups lagged behind.
5 min read
GLP-1R Regulates Blood Pressure via Kidney VSMCs, Study Finds
Researchers have pinpointed that GLP-1 receptors (GLP-1R) in kidney vascular smooth muscle cells play a crucial role in blood pressure regulation. In mouse studies, semaglutide lowered BP only when these receptors were intact, highlighting a novel pathway independent of weight loss. This could reshape our understanding of GLP-1 therapies in hypertension.
5 min read
What Is Orforglipron? New Oral Weight-Loss Pill Trial Results
A groundbreaking phase 3 trial shows orforglipron, a new daily oral weight-loss pill, surpassing oral semaglutide in blood sugar control and weight reduction for type 2 diabetes patients. This small-molecule GLP-1 agonist offers advantages over injectables like Ozempic by eliminating needles and refrigeration needs. However, higher gastrointestinal side effects raise questions about long-term tolerability.
5 min read
Telangana DCA Warns Against Unsupervised Semaglutide Use Amid Weight Loss Demand
The Telangana Drugs Control Administration (DCA) has issued a strong warning against unsupervised use of semaglutide, a popular GLP-1 drug for weight loss and Type-2 diabetes management. With generics now available from Sun Pharma, Dr. Reddy's, Zydus, and Glenmark following patent expiry, demand is surging—but so are risks like acute pancreatitis and kidney injury. Always consult a doctor for proper assessment and prescription.
5 min read
GLP-1 RAs Linked to Lower Mortality in Brain Metastases, T2DM Patients
For patients battling cancer with brain metastases and type 2 diabetes, GLP-1 receptor agonists may offer a survival edge. A retrospective study of over 19,000 patients found GLP-1 RA users had significantly lower all-cause mortality (HR 0.63) after matching. This benefit held across major cancers and most GLP-1 RA types.
5 min read
CDSCO Advisory Curbs Misleading Promotion of GLP-1 Obesity Drugs
India's CDSCO has issued a strict advisory against misleading promotions of prescription obesity drugs like GLP-1 receptor agonists. The regulator targets indirect ads, exaggerated claims, and efforts undermining lifestyle changes. This move reinforces ethical marketing and patient safety in obesity treatment.
4 min read
Could Ozempic and GLP-1s Help ADHD Symptoms?
People with ADHD report feeling calmer and more focused on GLP-1 drugs like Ozempic, originally for obesity and diabetes. Experts explain potential links to dopamine and reduced food cravings, but stress no clinical trials prove direct benefits. Find out the real story behind social media buzz and what to discuss with your doctor.
5 min read
20% of Eligible Youth Prescribed GLP-1 RAs, Study Finds
Just 20% of youth eligible for GLP-1 receptor agonists due to obesity are actually prescribed these medications, according to a recent Pediatrics study. Prescribing favors older adolescents with higher BMI and specific racial groups, but interruptions due to cost affect nearly two-thirds. This highlights gaps in access to promising obesity treatments for teens.
5 min read
Wegovy and Ozempic May Slash Deadly Heart Attack Complication Risk
Researchers from the University of Bristol and UCL have found that GLP-1 drugs like Wegovy and Ozempic could dramatically reduce the risk of 'no-reflow,' a deadly complication affecting up to half of heart attack patients. By relaxing tiny blood vessels, these medications may prevent further heart damage even if given by paramedics on-site. This study opens doors for repurposing popular obesity and diabetes treatments in emergency cardiac care.
6 min read
Semaglutide May Double nAMD Risk in Older Adults: Study
New research from the University of Toronto reveals that older adults with diabetes taking semaglutide (Ozempic and Wegovy) face more than double the risk of neovascular age-related macular degeneration (nAMD), a severe form of vision loss. The study, published in JAMA Ophthalmology, highlights increased risks with longer use and certain comorbidities. Patients should prioritize regular eye exams to catch issues early.
5 min read
Beyond Weight Loss: Ozempic Linked to Migraine Reduction, Study
GLP-1 receptor agonists like Ozempic, used for diabetes and weight loss, may offer relief for chronic migraine sufferers by cutting emergency department visits and medication needs. A new study compares them to topiramate, revealing promising associations in stabilizing migraine burden. Presented at the American Academy of Neurology's 2026 meeting, these findings highlight unexpected benefits beyond weight loss.
5 min read
Healthy Lifestyle Enhances GLP-1 Therapy's CV Benefits in Type 2 Diabetes
New research reveals that pairing GLP-1 receptor agonists with healthy lifestyle habits significantly lowers heart attack, stroke, and CV death risk in type 2 diabetes patients. Those following 6-8 habits plus GLP-1 therapy saw a 43% reduced MACE risk. This study highlights their complementary roles in heart health.
5 min read
Zydus Launches Affordable Semaglutide Brands in India on Patent Expiry
Zydus Lifesciences is set to launch affordable semaglutide injections in India right on patent expiry, targeting the growing Type 2 diabetes and obesity crisis. With innovative reusable pens under brands like SEMAGLYN, MASHEMA, and ALTERME, the company aims to cut costs and improve patient adherence. This move could transform access to GLP-1 therapy for millions.
6 min read
Tanmay Bhat on GLP-1 Drugs Failing Appetite Suppression & Genetic Report
Comedian Tanmay Bhat recently opened up about his disappointing experience with GLP-1 medications, reporting zero appetite suppression despite using them for weight management. He attributes this to a BDNF gene variant affecting satiety signaling, sparking discussions on genetic factors in treatment response. While many see benefits from drugs like semaglutide and tirzepatide, Bhat's story highlights why results vary.
5 min read
Ozempic-Like Drugs in India May Drop 50% in Price from March 2026
Semaglutide-based weight-loss drugs like Ozempic and Wegovy are set for a price revolution in India, with generics launching after patent expiry on March 20, 2026, potentially halving costs. Domestic giants like Sun Pharmaceutical and Dr. Reddy's are gearing up to make these GLP-1 therapies more affordable amid rising obesity rates. This shift could transform access to effective treatments for diabetes and weight management.
5 min read
Zydus Launches Semaglutide in Reusable Pen After Patent Expiry: Prices to Fall
Zydus Lifesciences is set to revolutionize semaglutide access in India with a reusable adjustable pen device after the patent expires on March 20. Brands like SEMAGLYN™, MASHEMA™, and ALTERMET™ promise easier dosing and lower prices around ₹3,500-4,000 per month. This move could expand GLP-1 therapy for Type 2 diabetes and obesity amid rising demand.
5 min read
GLP-1 RAs Reduce Food Noise by 46%, Emerging Evidence Shows
Emerging evidence suggests GLP-1 receptor agonists (GLP-1 RAs) not only aid weight loss but also significantly quiet 'food noise'—those persistent, distressing thoughts about food. In the US-based INFORM survey, 550 individuals using GLP-1s reported a 46% reduction in constant food thoughts, alongside mental health gains. This could redefine obesity management for better holistic outcomes.
6 min read
GLP-1s Show Promise in MS, But More Rigorous Research Needed
GLP-1 receptor agonists, originally developed for diabetes, are gaining attention for potential benefits in multiple sclerosis (MS) due to their effects on the brain and metabolic health. Expert Afsaneh Shirani, MD, highlighted promising studies at ACTRIMS, including weight loss and minimal relapses, but stressed the need for more rigorous trials. Key challenges like biomarkers, patient selection, and access remain.
6 min read
Types of Weight Loss Medications: Comparing Key Options
Weight loss medications are gaining attention for treating obesity and overweight, with eight approved types working in unique ways. From GLP-1 receptor agonists mimicking fullness hormones to stimulants like Qsymia reducing appetite, find out which might work best for your goals. This guide compares options, costs, and eligibility criteria to help you choose wisely.
6 min read
GLP-1 Activates KATP Channels in Coronary Pericytes for Cardioprotection
A new study in Nature Communications uncovers how GLP-1 activates ATP-sensitive potassium (KATP) channels in coronary pericytes, providing a novel cardioprotective mechanism through brain-gut-heart signaling. This discovery shifts focus from cardiomyocytes to the microvascular role of pericytes in enhancing myocardial blood flow. Understand the implications for GLP-1 receptor agonists in heart disease treatment.
7 min read
Oral Semaglutide Reduces Heart Failure Risk in Type 2 Diabetes: SOUL Trial
New analysis from the SOUL trial reveals oral semaglutide significantly reduces heart failure risks in type 2 diabetes patients who already have the condition. This benefit is especially notable in HFpEF cases, without compromising safety. Discover the details and implications for managing cardiometabolic disease.
5 min read
GLP-1 Drugs Reduce Mortality Risk in Type 1 Diabetes
A recent study indicates that GLP-1 receptor agonists and incretin-based drugs may decrease mortality risk and hospital visits for adults with type 1 diabetes. Researchers compared outcomes in users versus non-users, finding significant benefits across BMI categories. Further long-term studies are needed to confirm safety and efficacy.
3 min read
What is 'Food Noise' and Why It's Gaining Attention with the Surge in GLP-1 Drugs?
Before starting Ozempic in spring 2023, Brenda Rogers hadn't recognized how 'food noise' drained her mental stamina. This term describes a constant preoccupation with food, tied to GLP-1 medications for diabetes and obesity. Experts explain its causes, how drugs alleviate it, and alternative approaches like therapy and diet adjustments.
4 min read
GLP-1 Medications Outperform Metformin for Weight Management in Teens with Type 2 Diabetes
Research indicates that GLP-1 therapies offer enhanced weight benefits compared to metformin in adolescents diagnosed with type 2 diabetes. The study highlights comparable glycemic control with GLP-1 drugs but superior weight reduction.
4 min read
Weight Loss Jabs Warning: Risks of Unregulated Semaglutide & GLP-1s
Recent raids on illegal labs highlight the risks of unregulated weight loss medications. Learn how to protect your health and make informed decisions about your weight loss journey. Always consult with a healthcare professional.
4 min read
GLP-1 Injections: Unexpected Heart Health Benefits Unveiled
New research reveals that GLP-1 weight loss injections, such as semaglutide, may offer significant heart health benefits independent of weight loss. This could change how we view and use these medications for long-term health.
3 min read